OCGN Ocugen Dashboard

Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline includes OCU400, OCU410, OCU200, OCU200, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.

Company profile

Ticker

OCGN

Exchange

NASDAQ

Website

www.histogenics.com/

CEO

Shankar Musunuri

Incorporated

Delaware

Location

Pennsylvania

Fiscal year end

Dec 31

Sector

Manufacturing > Sanitary Paper Product Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Denali Therapeutics • Seagen ...

Former names

HISTOGENICS CORP

SEC CIK

0001372299

Corporate docs

Articles of Incorporation & Bylaws

OCGN stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Occugen Shares See Volume; Traders Circulate MumbaiMirror Report Highlighting Production Capacity Of Co's Covaxin Vaccine Will Be Doubled By May-June 2021

12 May 21

https://mumbaimirror.indiatimes.com/coronavirus/news/centre-to-augment-manufacturing-capacity-of-covaxin-under-mission-covid-suraksha/articleshow/82575470.cms

FDA To Hold AdCom Meeting For Expanding Use COVID-19 Vaccine In Children

10 May 21

The FDA’s Center for Biologics Evaluation and Research (CBER) will convene a virtual meeting of the Vaccines and Related Biological Products Advisory Committee on June 10

Cantor Fitzgerald Downgrades Ocugen to Neutral, Lowers Price Target to $11

7 May 21

Cantor Fitzgerald analyst Kristen Kluska downgrades Ocugen (NASDAQ:OCGN) from Overweight to Neutral and lowers the price target from $15 to $11.

Top 20 Searched Tickers In Benzinga Pro For Morning Of Friday, May 7, 2021

7 May 21

Benzinga Pro's Top 5 Stocks To Watch For Friday, May 7, 2021: JMIA, TLRY, WKHS, LEDS, OCGN

7 May 21

Press releases

Pro users get this 30m faster

Thinking about buying stock in Sundial Growers, Palisade Bio, Ocugen, Farmmi, or Bank of America?

13 May 21

NEW YORK, May 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, PALI, OCGN, FAMI, and BAC.

Thinking about buying stock in Palantir Technologies, Ocugen, RA Medical Systems, AMC Entertainment, or Zomedica?

12 May 21

NEW YORK, May 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PLTR, OCGN, RMED, AMC, and ZOM.

Thinking about buying stock in Sundial Growers, Plug Power, Naked Brand, Ocugen, or Nano Dimension?

11 May 21

NEW YORK, May 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, PLUG, NAKD, OCGN, and NNDM.

Thinking about buying stock in Sundial Growers, Palantir Technologies, Ocugen, Nokia, or Transocean?

10 May 21

Thinking about buying stock in Acasti Pharma, Ocugen, Castor Maritime, Naked Brand, or Auris Medical?

7 May 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

7 May 21

15 May 21

31 Dec 21

Financial summary

Financial statements Chart OCGN financial data

Quarter (USD)	Mar 21	Dec 20	Sep 20	Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Ocugen earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	44.94M	44.94M	44.94M	44.94M	44.94M	44.94M
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	2.35M	2.03M	1.76M	1.28M
Cash used (since last report)	n/a	n/a	3.51M	3.04M	2.63M	1.9M
Cash remaining	n/a	n/a	41.43M	41.91M	42.31M	43.04M
Runway (months of cash)	n/a	n/a	17.6	20.6	24.0	33.7

Beta Read what these cash burn values mean

Recent insider trades

OCGN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
14 May 21	Subramanian Sanjay	Common Stock	Sell	Dispose S	No	Yes	8.183	31,000	253.67K	45,591
14 May 21	Subramanian Sanjay	Common Stock	Option exercise	Aquire M	No	No	0.34	31,000	10.54K	76,591
14 May 21	Subramanian Sanjay	Option Common Stock	Option exercise	Dispose M	No	No	0.34	31,000	10.54K	338,256
4 May 21	Tammara Vijay	Common Stock	Sell	Dispose S	No	Yes	13.81	2,311	31.91K	0
4 May 21	Tammara Vijay	Common Stock	Option exercise	Aquire M	No	No	0.565	2,311	1.31K	2,311
4 May 21	Tammara Vijay	Common Stock	Sell	Dispose S	No	Yes	13.5	6,500	87.75K	0
4 May 21	Tammara Vijay	Common Stock	Option exercise	Aquire M	No	No	0.51	6,500	3.32K	6,500
4 May 21	Tammara Vijay	Common Stock	Sell	Dispose S	No	Yes	13.81	2,000	27.62K	0
4 May 21	Tammara Vijay	Common Stock	Option exercise	Aquire M	No	No	2.94	2,000	5.88K	2,000
4 May 21	Tammara Vijay	Common Stock	Sell	Dispose S	No	Yes	13.81	4,900	67.67K	0

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

OCGN institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders	Current	Prev Q	Change
Total holders	0	16	EXIT
Opened positions	0	4	EXIT
Closed positions	16	7	+128.6%
Increased positions	0	9	EXIT
Reduced positions	0	1	EXIT

13F shares	Current	Prev Q	Change
Total value	0	4.28M	EXIT
Total shares	0	13.81M	EXIT
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Empery Asset Management	0	$0

Largest transactions	Shares	Bought/sold	Change
Vanguard	0	-7.44M	EXIT
BLK Blackrock	0	-5.02M	EXIT
Geode Capital Management	0	-545.34K	EXIT
WINTON	0	-372.09K	EXIT
NTRS Northern Trust	0	-136.66K	EXIT
UBS UBS Group AG - Registered Shares	0	-80.25K	EXIT
Sit Investment Associates	0	-75K	EXIT
JPM JPMorgan Chase & Co.	0	-65.3K	EXIT
Susquehanna International	0	-22.03K	EXIT
Patriot Investment Management	0	-20K	EXIT

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Regeneron Pharmaceuticals • Vericel • Novavax • Ocular Therapeutix • Adverum Biotechnologies • Regenxbio • ProQR Therapeutics • Moderna • MeiraGTx • BioNTech SE

Risks

The ongoing COVID-19 pandemic and actions taken in response to it may result in disruptions to our business operations, which would have a material adverse effect on our business, financial position, operating results, and cash flows.

Management Discussion

Research and development expense increased by $1.2 million for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. The increase was primarily due to an increase of $0.7 million related to OCU400 preclinical activities, $0.4 million related to COVAXIN development, $0.3 million related to OCU200 preclinical activities, $0.2 million related to professional fees, and $0.1 million related to stock-based compensation expense, partially offset by a decrease of $0.5 million related to the discontinuation of OCU300 clinical trial activities in 2020.
General and administrative expense increased by $1.9 million for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. The increase was primarily due to incurring $1.2 million in costs associated with obtaining an increase in the authorized shares of our common stock including proxy solicitation fees and an increase of $0.5 million related
to stock-based compensation expense. See Note 12 in the notes to the condensed consolidated financial statements included in this report for additional information about the increase in the authorized shares of our common stock.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: abroad, accuracy, adjuvant, age, antigen, assert, asymptomatic, attract, Bharat, Biotech, BLA, Brazilian, breach, broadly, capable, cellular, certainty, Certificate, chain, China, CMC, complicate, confidence, confidentiality, congenital, contact, convenience, Council, covaxin, Delaware, demonstrated, dissolution, diverse, diversion, domain, domestic, dosed, double, durability, duration, EC, EMA, EUA, Europe, European, eventually, exhaustive, Expansion, experiencing, export, Finnerty, foreign, found, fullest, fully, furniture, global, globally, Good, Governor, harm, healthcare, Hedging, IgG, Immunoglobulin, impede, improvement, inactivated, incomplete, incorporated, Incorporation, indemnification, India, Indian, indirect, infection, inquiry, Institute, institutional, integrity, interrupt, interval, intervention, lab, Lancet, large, LCA, leasehold, leber, maintenance, Master, Medicinal, memory, mild, moderate, movement, mutant, national, Nonretirement, nucleocapsid, OMPD, overhead, overwhelmed, owner, oxygen, par, path, payroll, point, practicable, Practice, Preferred, prevent, prevention, proxy, published, quarantine, RBD, receipt, recession, reclassification, recruit, regimen, registered, relevant, rely, resource, retain, retaining, review, save, scientific, shipping, shorter, skilled, slowdown, solicitation, spectrum, spike, spread, storage, stored, stringent, strong, suggest, suggested, surge, suspension, temporary, Territory, thereon, TM, tracked, travel, uncertain, unduly, unpredictable, vaccination, vaccine, variant, Virology, vitro, waiting, wave, world, Wuhan, York

Removed: accreted, accretion, accurate, acquirer, acquisition, acting, actively, amend, amortization, amounted, announced, arise, assessed, assistance, attributable, bear, beginning, behalf, bid, bifurcated, bill, binding, bolster, case, caution, choroidal, combination, combined, comparable, comparative, concentrated, Concurrently, consecutive, constituted, consummation, contemplated, Contemporaneously, convert, corporation, coupon, covering, decreased, deemed, deficiency, delisting, depreciated, derivative, directly, director, discovering, discretionary, disposed, dividing, doubt, effected, eighteen, encounter, encountered, entirety, established, exchanged, exercised, existing, expressly, extinguish, extraordinary, eye, fact, factor, falling, favorable, feature, forma, frequently, frozen, goal, harbor, history, host, identifiable, implemented, impracticable, inability, increasing, industry, initially, intangible, July, knowledge, legally, letter, lieu, listing, Litigation, lower, lowest, manage, manner, marketed, maturity, measured, Medavate, merged, modified, month, multiplying, Musunuri, myopic, nasdaq, NeoCart, neovascularization, occlusion, occurrence, oral, owed, percentage, permit, person, placement, prepay, pro, production, pursuing, qualified, ranging, recent, recognition, recourse, recycled, redeem, redemption, reduced, Reform, regain, release, Reorganization, replaced, requirement, resale, reset, resolution, respiratory, retroactively, reverse, safe, scheduled, seek, senior, Shankar, showed, single, site, spending, structure, structured, sublicense, subscription, surviving, sweeping, symptom, terminology, thereunder, threatened, threshold, tolled, Tolling, trading, transformative, unanticipated, unforeseen, variety, vein, vi, viability, volume, warrant, written

From filing 10-Q 2021 Q1